Opus Genetics Files Form 144 for Proposed Securities Sale
Ticker: IRD · Form: 144 · Filed: Apr 23, 2026 · CIK: 0001228627
Sentiment: neutral
Topics: insider-filing, securities-sale, form-144
TL;DR
Yerxa filing 144 for Opus Genetics - potential sell-off incoming.
AI Summary
Benjamin R. Yerxa, reporting for Opus Genetics, Inc., filed a Form 144 on April 23, 2026, indicating a proposed sale of securities. The filing provides mailing and business addresses for both Inspire Pharmaceuticals, Inc. and Opus Genetics, Inc., with Opus Genetics being a Delaware-incorporated company in the Pharmaceutical Preparations sector.
Why It Matters
This filing signals potential insider selling or a planned divestment of shares by an individual associated with Opus Genetics, which could impact the stock's supply and demand dynamics.
Risk Assessment
Risk Level: medium — Form 144 filings indicate proposed sales, which can introduce selling pressure and uncertainty for the stock.
Key Players & Entities
- Benjamin R. Yerxa (person) — Reporting individual
- Opus Genetics, Inc. (company) — Subject company
- Inspire Pharmaceuticals, Inc. (company) — Mailing address recipient
- 2026-04-23 (date) — Filing date
FAQ
What is the purpose of a Form 144 filing?
A Form 144 filing is a notice of proposed sale of restricted securities or control securities.
Who is Benjamin R. Yerxa in relation to Opus Genetics, Inc.?
Benjamin R. Yerxa is listed as the reporting individual for Opus Genetics, Inc. in this filing.
When was this Form 144 filed?
The Form 144 was filed on April 23, 2026.
What industry does Opus Genetics, Inc. operate in?
Opus Genetics, Inc. operates in the Pharmaceutical Preparations sector (SIC 2834).
What is the state of incorporation for Opus Genetics, Inc.?
Opus Genetics, Inc. is incorporated in Delaware (DE).
Filing Details
This Form 144 (Form 144) was filed with the SEC on April 23, 2026 by Benjamin R. Yerxa regarding Opus Genetics, Inc. (IRD).